R.E.N.A.L. Score's Impact on Kidney Cancer Radiation Treatment Outcomes

What is it about?

This research discusses a study evaluating the predictive value of the R.E.N.A.L. nephrometry score (RNS) for outcomes following stereotactic ablative body radiotherapy (SABR) for primary renal cell carcinoma (RCC). The study analyzed 90 patients with a median age of 77 years and a median follow-up of 4.8 years. Most patients had moderate-complex renal tumours with a median RNS of 9. The results showed a decline in estimated glomerular filtration rate (eGFR) of 8.1 mL/min/1.73 m² at 1 year post-SABR. The study found a potential association between baseline RNS and renal function trajectories (P = 0.06). SABR demonstrated effectiveness with acceptable renal function decline and toxicity for medically inoperable patients with complex primary kidney tumours. The study concludes that SABR is a viable treatment option for these patients, and further investigation into the relationship between RNS and renal function outcomes is warranted.

Featured Image

Why is it important?

This research is significant because it evaluates the predictive value of the R.E.N.A.L. nephrometry score (RNS) for outcomes following stereotactic ablative body radiotherapy (SABR) in primary renal cell carcinoma (RCC) patients. Understanding the impact of tumor complexity on SABR outcomes is crucial for improving treatment planning and patient care. The study provides valuable insights into the effectiveness and safety of SABR as a nephron-sparing treatment option for patients with complex primary kidney tumors who are medically inoperable. This research contributes to the growing body of evidence supporting SABR as an alternative treatment modality, potentially expanding treatment options for patients with RCC. Key Takeaways: 1. Treatment Efficacy: SABR demonstrates effectiveness as a treatment option for primary RCC, with a 3-year freedom from local failure rate of 97% and only 3.3% of patients experiencing local progression. 2. Renal Function Impact: The study shows an acceptable decline in renal function following SABR, with a median decrease in eGFR of 8.1 mL/min/1.73 m2 at 1 year, and only 2.2% of patients requiring dialysis post-treatment. 3. Safety Profile: SABR exhibits a favorable toxicity profile, with only 4.4% of patients experiencing Grade 3 toxicities, suggesting it is a safe alternative for medically inoperable patients with complex primary kidney tumors.